Schafer Cullen Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-393,985
| Closed | -$18.1M | – | 105 |
|
|
2020
Q4 | $18.1M | Sell |
393,985
-585,117
| -60% | -$26.9M | 0.27% | 78 |
|
|
2020
Q3 | $46.1M | Sell |
979,102
-77,912
| -7% | -$3.9M | 0.72% | 52 |
|
|
2020
Q2 | $53.9M | Sell |
1,057,014
-32,002
| -3% | -$1.64M | 0.83% | 42 |
|
|
2020
Q1 | $51.6M | Sell |
1,089,016
-64,818
| -6% | -$3.46M | 0.86% | 42 |
|
|
2019
Q4 | $67.8M | Sell |
1,153,834
-42,325
| -4% | -$2.35M | 0.8% | 42 |
|
|
2019
Q3 | $63.8M | Buy |
1,196,159
+32,405
| +3% | +$1.67M | 0.77% | 45 |
|
|
2019
Q2 | $58.8M | Buy |
1,163,754
+156,910
| +16% | +$7.87M | 0.69% | 50 |
|
|
2019
Q1 | $52.6M | Sell |
1,006,844
-65,530
| -6% | -$3.27M | 0.77% | 44 |
|
|
2018
Q4 | $51.2M | Sell |
1,072,374
-205,163
| -16% | -$10.1M | 0.79% | 46 |
|
|
2018
Q3 | $64.1M | Sell |
1,277,537
-125,694
| -9% | -$6.39M | 0.83% | 53 |
|
|
2018
Q2 | $70.7M | Sell |
1,403,231
-93,538
| -6% | -$4.71M | 0.91% | 51 |
|
|
2018
Q1 | $73.1M | Buy |
1,496,769
+597,939
| +67% | +$27.8M | 0.88% | 54 |
|
|
2017
Q4 | $39.9M | Sell |
898,830
-620,716
| -41% | -$28.7M | 0.46% | 73 |
|
|
2017
Q3 | $77.1M | Sell |
1,519,546
-77,920
| -5% | -$3.95M | 0.93% | 48 |
|
|
2017
Q2 | $86.1M | Sell |
1,597,466
-246,841
| -13% | -$13.2M | 1.07% | 41 |
|
|
2017
Q1 | $97.2M | Buy |
1,844,307
+124,982
| +7% | +$6.34M | 1.25% | 33 |
|
|
2016
Q4 | $82.8M | Sell |
1,719,325
-225,617
| -12% | -$11.1M | 1.12% | 37 |
|
|
2016
Q3 | $105M | Buy |
1,944,942
+141,684
| +8% | +$7.77M | 1.26% | 37 |
|
|
2016
Q2 | $97.7M | Sell |
1,803,258
-7,288
| -0.4% | -$384K | 1.19% | 40 |
|
|
2016
Q1 | $91.8M | Sell |
1,810,546
-84,456
| -4% | -$4.21M | 1.12% | 43 |
|
|
2015
Q4 | $95.6M | Sell |
1,895,002
-317,096
| -14% | -$16.2M | 1.14% | 42 |
|
|
2015
Q3 | $106M | Sell |
2,212,098
-22,855
| -1% | -$1.19M | 1.22% | 39 |
|
|
2015
Q2 | $116M | Buy |
2,234,953
+3,468
| +0.2% | +$195K | 1.2% | 37 |
|
|
2015
Q1 | $129M | Buy |
2,231,485
+882,904
| +65% | +$50.6M | 1.28% | 37 |
|
|
2014
Q4 | $72M | Sell |
1,348,581
-980,149
| -42% | -$54.8M | 0.91% | 37 |
|
|
2014
Q3 | $134M | Buy |
2,328,730
+114,957
| +5% | +$7.05M | 1.28% | 34 |
|
|
2014
Q2 | $148M | Buy |
2,213,773
+215,903
| +11% | +$14.6M | 1.36% | 33 |
|
|
2014
Q1 | $133M | Buy |
1,997,870
+313,201
| +19% | +$21.2M | 1.29% | 34 |
|
|
2013
Q4 | $112M | Buy |
1,684,669
+227,757
| +16% | +$14.8M | 1.11% | 36 |
|
|
2013
Q3 | $91.4M | Buy |
1,456,912
+217,738
| +18% | +$14M | 1.01% | 36 |
|
|
2013
Q2 | $77.4M | Buy |
+1,239,174
| New | +$78.7M | 0.92% | 35 |
|
Other funds holding GSK
BCIM